Drug Profile
Research programme: small molecule therapeutics - Envigen Pharmaceuticals
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator ENVIGEN Pharmaceuticals
- Class Antineoplastics; Antivirals; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; HIV infections; Neurological disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Cancer in USA
- 28 May 2022 No recent reports of development identified for research development in HIV-infections in USA
- 28 May 2022 No recent reports of development identified for research development in Neurological-disorders in USA